Nath Bio-Genes (India) Limited files substantial acquisition disclosure under SEBI Takeover Code
Nath Bio-Genes (India) Limited has submitted a mandatory disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as required when a party acquires shares or voting rights exceeding specified thresholds. The disclosure was filed with the NSE. The filing triggers transparency requirements and may necessitate an open offer if the acquirer crosses the 26% threshold or if specified conditions are met under the Takeover Code.
Why it mattersThe filing indicates a threshold acquisition (typically 5% or more) has occurred or is being announced; partners must review the detailed disclosure for acquirer identity, shareholding pattern post-transaction, and any open offer obligations under Regulation 38 of the Takeover Code.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives – Official Disclosure · official
- SEBI Official – Takeover Regulations Text · official
- NSE Listing Rules – Continuous Disclosure Requirements · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Trilegal acts on Berry Street - Healthify merger27 Aug 2026
- ChrysCapital-backed KIMS in talks to acquire minority stake in Renova Hospitals for $52M25-26 Aug 2026 · $52 million
- Mankind Pharma Limited: Other Restructuring26 Aug 2026
- Mankind Pharma Limited: Outcome of Board Meeting26 Aug 2026